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57 ABSTRACT 
Heavily fluorinated Sugar analogs of formula 
R1 O R2 
F F O 
F F 
II 
R1 
F R 2 
O 
F F 
F 
F F 
wherein R is selected from alkyl, alkenyl, aryl, CH-OH, 
-CH-O-alkyl, -CH2-O-aryl, -CHOPOH, 
-CH-O-carbohydrate, -CH-NH-peptide, or 
-CH-O-peptide; 
wherein R is selected from hydroxy, -O-carbohydrate, 
-NH-peptide, 
NH2 
ls 
s s 
O 
HN 
1s, 
R4 O 
N21 N HN N 
- N o Rs N 
wherein R is selected from H, halogen, lower alkyl, 
lower alkenyl, lower haloalkyl, lower haloalkenyl, 
amino, mono- or di-lower alkylamino; 
wherein R is Selected from amino, hydroxy, alkoxy, or 
halogen; and 
wherein Rs is H or amino. The compounds of formula 
(I) are useful as antiviral and antineoplastic agents 
and the compounds of formula (II) are useful as plant 
growth inhibitors and herbicides. Also disclosed is a 
method for preparing the heavily fluorinated Sugars 
of the present invention which utilizes inexpensive 
Starting materials which incorporate the desired 
number of fluorine moieties and a new reagent, 
benzyloxymethylzinc bromide, for introducing the 
5'-hydroxymethyl moiety. The synthetic method of 
the present invention is advantageous in that it does 
not require late Stage fluorination Step. 
24 Claims, 2 Drawing Sheets 
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HEAVILY FLUORINATED SUGAR ANALOGS 
RELATED APPLICATION 
This application claims priority under 35 U.S.C. S 119(e) 
to U.S. provisional application Ser. No. 60/026,459, filed 
Sep. 25, 1996. 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
The present invention relates to heavily fluorinated Sugar 
molecules, a method for the preparation thereof, and their 
use as antiviral and antineoplastic agents, glycosidase 
inhibitors, plant growth regulators and herbicides, and as 
intermediates for the preparation of heavily fluorinated 
oligo- and polysaccharides. The present invention also 
relates to a new starting material for the preparation of the 
heavily fluorinated Sugar analogs of the present invention. 
2. Description of the Prior Art 
Nucleotides perform a large number of functions for 
living organisms. For example, nucleotides Serve as the 
basic building blocks for RNA and DNA, store and transfer 
the essential chemical energy that propels metabolism, acti 
Vate chemical bonds for enzymatic reactions, control 
glycolysis, regulate the process of cell to cell 
communication, and perform a large number of other essen 
tial tasks. Because they are crucial to Such a wide variety of 
essential biochemical tasks, nature has designed exquisitely 
Selective enzymes for this class of compounds. 
Neoplastic or viral diseases, in contrast to bacterial 
diseases, have proved difficult to treat. While bacterial 
diseases have a number of biochemical processes that are 
distinct to the organism, Viruses use the cellular machinery 
of the infected host cell, and there are relatively few virus 
Specific processes that can be inhibited Selectively. 
Similarly, tumor cells are mutated variants of normal cells 
and rely on many of the same biochemical pathways. 
Therefore, chemotherapies targeted for these diseases are 
often highly toxic due to the lack of selectivity of the 
compound for diseased cells. One characteristic that marks 
both virally infected cells and tumor cells is their propensity 
for rapid growth. Since growth involves synthesis of DNA 
and RNA, these cells require a greater flux of nucleotides in 
comparison to normal cells, and often the diseased cell 
contains enzymes which are leSS Selective for nucleotides 
than their counterparts in normal cells. Therefore, nucleotide 
analogs may act as Substrates for the disease State enzymes, 
while they are virtually ignored by normal enzymes. This is 
the rationale for design of therapeutic nucleotide or nucleo 
side analogs, such as IUDR, trifluorothymidine, AZT, Ara 
A, ribavirin, acyclovir, ganciclovir, gemcitabine, MDL-101, 
731. Research on derivatives of nucleoside and nucleotide 
analogs continues to be intense. AS the above examples 
Show, modification on the base and Sugar moieties is poS 
Sible and in Some case, desirable. Recently, there has been 
a great deal of interest in fluorinated derivatives in which 
fluorine is incorporated into the Sugar nucleus. Gemcitabine 
(Eli Lilly) is now heading to market as an antiviral as well 
as a treatment for non Small cell lung cancer. Pancreatic 
cancer Studies are also underway. The fluorine Substituents 
help Stabilize the Sugar against glycolysis and improve the 
oral bioavailability of the drug. MDL 101,731 is active 
against breast, prostate, and colon cancers. Although nucleo 
Side analogs containing fluorine in the Sugar nucleus are 
known in the art, such as gemcitabine and MDL-101,731, 
the prior art compounds only contain one or two fluorine 
substituents. See also U.S. Pat. Nos. 4.963,662 (Matthes et 
al.), 5,153,180 (Matthes et al.), and 4,762,823 (Watannabe et 
al.). 
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SUMMARY OF THE INVENTION 
It is an object of the present invention to provide heavily 
fluorinated Sugar analogs containing a tetrafluoroethylene 
unit (-CFCF-) in the Sugar nucleus of ribose based 
nucleoside analogs and a hexafluorotrimethylene unit 
(-CFCFCF-) in the Sugar nucleus of hexose based 
nucleoside analogs. 
Another object of the present invention is to provide a 
synthetic method for easily obtaining the heavily fluorinated 
Sugar analogs which provides for a higher degree of fluo 
rination than is obtainable in the prior art methods, and 
which does not require a fluorination Step at or near the end 
of the synthesis. 
Another object of the present invention is to provide a 
novel Starting material for the production of heavily fluori 
nated SugarS. 
Yet another object of the present invention is to provide a 
method for the treatment of viral and neoplastic diseases by 
administering a pharmaceutically effective amount of the 
heavily fluorinated nucleoside analogs according to the 
present invention to a patient in need thereof. 
A further object of the present invention is to provide for 
a method of inhibiting glycosidases by administering a 
pharmaceutically effective amount of the heavily fluorinated 
nucleoside analogs according to the present invention to a 
patient in need thereof, Such as a patient with diabetes 
mellitus. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 shows an X-ray crystal determination of compound 
2. 
FIG.2 shows an X-ray crystal determination of compound 
7. 
DETAILED DESCRIPTION OF THE 
INVENTION 
The objects of the present invention are provided by the 
heavily fluorinated Sugar analogs of formula: 
R1 O R2 
F F O 
F F 
II 
R1 
F R 
O 2 
F F 
F 
F F 
wherein R is selected from alkyl, alkenyl, aryl, CHOH, 
-CH2-O-alkyl, -CH2-O-aryl, -CHOPOH, 
-CH-O-carbohydrate, -CH-NH-peptide, or 
-CH-O-peptide; 
wherein R is selected from hydroxy, -O-carbohydrate, 
-NH-peptide, 
6,013,790 
O NH2 
HN R3 N21 
1s, 1s, 
s s 
R4 O 
N21 N HN N 
- N Rs N 
wherein R is Selected from H, halogen, lower alkyl, 
lower alkenyl, lower haloalkyl, lower haloalkenyl, 
amino, mono- or di-lower alkylamino; 
wherein R is Selected from amino, hydroxy, alkoxy, or 
halogen; and 
wherein R is H or amino. 
The compounds according to the present invention are 
intended to encompass all Stereoisomers and mixtures 
thereof. 
Halogen includes fluorine, chlorine, bromine, or iodine. 
Lower alkyl includes branched or Straight chain alkyl groups 
having from 1 to about 10 carbon atoms. Lower haloalkyl 
includes branched or Straight chain alkyl groups having from 
1 to about 10 carbon atoms mono-, di-, or trisubstituted, or 
higher, by fluorine, chlorine, bromine, or iodine, Such as 
monofluoromethyl, difluoromethyl, trifluoromethyl, etc. 
Lower alkenyl includes branched or Straight chain alkenyl 
groups having from 1 to about 10 carbon atoms, having one 
or more carbon-carbon double bonds. Lower haloalkenyl 
includes branched or Straight chain alkenyl groups having 
from 1 to about 10 carbon atoms having one or more 
carbon-carbon double bonds mono-, di-, or trisubstituted, or 
higher, by fluorine, chlorine, bromine, or iodine. Typical 
carbohydrates in the definition of R and R include, for 
example, mono-, di-, oligo-, or polysaccharides, Such as 
glucose, galactose, and the like. Typical peptides in the 
definition of R and R2 include, for example, naturally 
occurring or Synthetic amino acids, or di-, oligo-, or 
polypeptides, derived from naturally occurring or Synthetic 
amino acids. 
The compounds according to the present invention 
according to formula (I) find utility as antiviral and antine 
oplastic agents, and as glycosidase inhibitors. The com 
pounds according to formula (II) are useful as plant growth 
inhibitors, glycosidase inhibitors, and herbicides. 
A further aspect of the present invention relates to pro 
ceSSes for preparing heavily fluorinated Sugars and Starting 
materials and intermediates useful therein. 
It will be understood that the reactions in which the novel 
heavily fluorinated carbohydrates according to the present 
invention are coupled with the bases are frequently of a 
nature Such that the hydroxy groups should be protected to 
keep them from reacting with the base, or being decomposed 
in Some manner. The protecting groups are chosen from the 
groupS used in Synthetic organic chemistry for the purpose. 
Chemists are accustomed to choosing groups which can be 
efficiently placed on hydroxy groups, and which can be 
easily removed when the desired reaction is complete. 
Suitable groups are described in Standard textbooks, Such as 
Chapter 3 of Protective Groups in Organic Chemistry, 
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McOmie, Ed., Plenum Press, New York (1973); and Chapter 
2 of Protective Groups in Organic Synthesis, Greene, John 
Wiley & Sons, New York (1981). 
Typical hydroxy-protecting groups include formyl, 
2-chloroacetyl, benzyl, diphenylmethyl, triphenylmethyl, 
4-nitrobenzyl, phenoxycarbonyl, t-butyl, methoxymethyl, 
tetrahydropy ranyl, ally l, tetrahydro thie nyl, 
2-methoxyethoxymethyl, methoxyacetyl, phenoxyacetyl, 
isobutyryl, ethoxycarbonyl, benzyloxycarbonyl and the like. 
Sillyl hydroxy-protecting groups are often particularly 
convenient, because most of them are easily cleaved by 
contact with water or an alcohol. Such groups include 
especially trimethylsilyl, as well as isopropyldimethylsilyl, 
methyl diisopropyl Sily l, trii Sopropyl Sillyl, 
t-butylidimethylsilyl, and the like. 
Heavily fluorinated carbohydrates may have a hydroxy 
group at the 1-position of its ring, and in order to react the 
heavily fluorinated Sugars with a base to form the heavily 
fluorinated nucleoside analogs according to the present 
invention, it is necessary to place a leaving group at the 
1-position. The leaving groupS used are typical of those used 
commonly in organic Synthesis. The preferred leaving 
groups are Sulfonates, of which the most preferred is meth 
anesulfonate; other typical leaving groups Such as 
toluenesulfonate, ethaneSulfonate, isopropanesulfonate, 
4-methoxybenzeneSulfonate, 4-nitrobenzeneSulfonate, and 
2-chlorobenzenesulfonate. Chloro and bromo may also be 
used. 
An appropriate leaving group may be placed at the 
1-position of the heavily fluorinated Sugar. The preferred 
leaving group is methaneSulfonyl, which may be readily 
provided by reaction with methanesulfonyl chloride in the 
presence of an equivalent amount of a Suitable acid Scav 
enger Such as triethylamine and the like. Other Sulfonyl 
leaving groups may be provided in the same way by reaction 
with the appropriate Sulfonyl halide. 
The purine and/or pyrimidine bases used to form the 
heavily fluorinated nucleoside analogs according to the 
present invention are commonly known to those skilled in 
the art, and no discussion of their Synthesis is necessary. 
However, the primary amino groups which are present on 
Some of the bases should be protected before the base is 
coupled with the heavily fluorinated Sugars. The usual 
amino-protecting groups are used, including silyl groups 
Such as have been discussed, as well as Such typical groups 
as t-bu to Xy carbonyl, ben Zylo Xy carbonyl, 
4-methoxybenzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 
formyl, acetyl, and the like. 
It is often advisable to convert keto oxygen atoms on the 
bases to the enol form, in order to make the bases more 
highly aromatic and thereby allow more ready attack of the 
base by the carbohydrate. It is most convenient to enolize the 
oxygens by providing silyl protecting groups for them. The 
usual Silyl protecting groups as discussed above are used for 
this purpose, also. 
The reaction between the protected heavily fluorinated 
Sugar and the base may be carried out neat at an elevated 
temperature in the range of from about 50 C. to about 200 
C. It is also possible to use relatively high-boiling Solvents 
for the reaction, Such as dimethylformamide, 
dimethylacetamide, hexamethylphosphoramide and the like. 
However, if the coupling reaction is carried out under 
elevated pressure, to avoid distillation of a low-boiling 
Solvent, any convenient inert reaction Solvent can be used. 
The coupling reaction may be done at low temperatures if 
reaction initiator, Such S 
trifluoromethaneSulfonyloxysilane, is used. The usual inert 
6,013,790 
S 
reaction Solvents, Such as tetrahydrofuran, diethyl ether, 
halogenated alkanes Such as chloroform, dichloromethane, 
trichloroethane and the like, and aromatics including Such 
Solvents as benzene, toluene and the Xylenes may be used. 
The final Step of the reaction Sequence is the removal of 
the protecting groups. Most silyl protecting groups may be 
easily cleaved by contact with water or an alcohol. The 
t-butyldimethylsilyl protecting group requires acid 
conditions, Such as contact with gaseous hydrogen halide, 
for its removal. 
Acyl protecting groups may be removed by Simple 
hydrolysis with Strong or moderately strong bases, Such as 
alkali metal hydroxides, at temperatures from about the 
ambient temperature to about 100° C. Such hydrolyses may 
be conveniently carried out in hydroxylic Solvents, espe 
cially aqueous alkanols. The reactions may also be carried 
out in any convenient Solvent, Such as polyols including 
ethylene glycol, etherS Such as tetrahydrofuran and the like, 
ketones Such as acetone and methyl ethyl ketone and other 
polar Solvents Such as dimethylsulfoxide. The cleavage of 
acyl protecting groups may also be performed with other 
bases, including, for example, Sodium methoxide, potassium 
t-butoxide, hydrazine, hydroxylamine, ammonia, alkali 
metal amides and Secondary amines Such as diethylamine 
and the like. The acyl protecting groups can also be removed 
with acid catalysts, Such as methaneSulfonic acid, hydro 
chloric acid, hydrobromic acid, Sulfuric acid, or with acidic 
ion eXchange resins. The removal of protecting groups 
which are ethers is carried out by known methods, for 
example, with ethanethiol and aluminum chloride. 
A preferred Synthetic method for preparing compounds 
and intermediates according to the present invention is 
described below. 
Heavily fluorinated sugar derivative of Formula (III): 
(III) 
(CF2) H 
C-R 
wherein R is selected from alkyl, alkenyl, aryl, CHOH, 
-CH2-O-alkyl, -CH2-O-aryl, -CHOPOH, 
-CH-O-carbohydrate, -CH-NH-peptide, or 
-CH-O-peptide; 
wherein R is selected from hydroxy, -O-carbohydrate, 
-NH-peptide, 
O NH2 
HN R3 N21 
1. N 1. N 
15 
25 
35 
40 
45 
50 
55 
60 
65 
6 
-continued 
R4 O 
N 
N HN N 
Rs N 
O 
wherein R is Selected from H, halogen, lower alkyl, 
lower alkenyl, lower haloalkyl, lower haloalkenyl, 
amino, mono- or di-lower alkylamino; 
wherein R is selected from amino, hydroxy, alkoxy, or 
halogen; 
wherein Rs is H or amino; and 
wherein n=2 or 3; 
may be prepared by converting one of the carboxylic ester 
groups of Formula (IV): 
loweralkyl-O-C(O)-(CF)-C(O)-O-loweralkyl (IV) 
wherein n=2 or 3, to the ketone to yield compounds of 
Formula (V): 
2-furyl-C(O)-(CF)-C(O)-O-loweralkyl (V) 
and then contacting a compound of Formula (V) with a 
reducing agent to form compounds of Formula (VI): 
(VI) 
\ N 
O 
(CR) - 
C-OH. 
H 
The hydroxy group of the compound of Formula (VI) may 
be protected with a protecting group to form compounds of 
Formula (VII): 
(VII) 
\ N 
O 
(CF2) 
-O-Protecting Group. 
The furyl group is converted to the carboxyl group by 
oxidation, to form compounds of Formula (VIII): 
6,013,790 
(VIII) 
O OH 
(CF2) C-O 
C-O-Protecting Group. 1O 
The carboxyl group of compounds of Formula (VIII) may be 15 
reduced to a hydroxymethyl group to form compounds of 
Formula (IX): 
(DX) 20 
OH 
(CF2) C-O 
25 
C-O-Protecting Group. 
H 
3O 
The protecting group of the compounds of Formula (IX) 
may be removed to produce compounds of Formula (X): 
(X) 35 
OH 
(CF2) $ 
40 
C-OH. 
H 
45 
Alternatively, the hydroxy group of the compound of 
Formula (IX) may also be protected to form compounds of 
Formula (XI): 50 
(XI) 
O-Protecting Group 
r 55 (CR) - 
-O-Protecting Group. 60 
These procedures are general and can be successfully as 
used for the introduction of any R-group in the terminal 
position. Examples include those shown in Formula (XII): 
wherein R is alkyl, alkenyl, aryl, CH-OH, CHO-alkyl, 
CHO-aryl, CHOPOH, CH-O-carbohydrate, CH-NH 
peptide, or CH-O-peptide. 
Additionally, essentially any carbohydrate residue or 
amino acid or peptide residue can be introduced at the 
1-position to form the compounds of formula (XIII): 
Carbohydrate 
or Formula (XIV): 
Peptide 
o1 
These general procedures are employed in the preparation 
of the compounds of the present invention in the Examples 
below. Moisture Sensitive reactions were run under a nitro 
gen atmosphere using oven dried Schlenk-type glassware. 
Commercially available high grade purity reagents were 
used without further purification. THF was distilled from Na 
and benzophenone, CHCl was distilled from CaH2. TEA 
and DEA were stored over molecular sieves and KOH, 
respectively. Analytical Samples were obtained by prepara 
tive TLC using Whatman PK5F silica plates with fluorescent 
indicator or by recrystallization. Deuterated chloroform and 
acetone were Stored over basic alumina and filtered through 
Sand directly in the Sample tube. Melting points are uncor 
rected. 
NMR Spectroscopy data is reported in the following 
Examples as follows. Since compounds 2, 3, 4, 5, and 7 can 
be obtained in high de following the experimental protocol, 
and the two cis and trans-1.5 diastereomers cannot be 
Separated by Simple column chromatography, the NMR data 
are reported for the major diastereomer only. HETCOR, 
COSY, H, C, F, 'F decoupled 'H, H decoupled 'F, 
and 'F decoupled 'C experiments were run on a 500 MHz 
General Electric instrument. H NMR were also run on a 
360 MHZ Tecmag-Nicolet instrument. Standard resolution 
enhancement algorithms were applied to the 'H, C, F, 
and cross-decoupled spectra. When the assignment of CF 
mutiplicity on the C is complicated by the presence of 
overlapping Signals, and/or low S/n ratio the chemical shift 
is given based on 'F decoupled 'C data. 
  
  
6,013,790 
9 
The following preparations and examples further illus 
trate the Synthesis of compounds of the present invention. 
Diethyl 2,2,3,3,4,4-hexafluoropentanoate. Large quanti 
ties of commercially available diester was prepared using 
Standard esterification procedure from the corresponding 
diacid. An ethanol Solution (250 mL) containing 2,2,3,3,4, 
4-hexafluoroglutaric acid (11.23g, 47.0 mmol) and concen 
trated Sulfuric acid (5 mL) was refluxed for 7 days using a 
Soxlet apparatus and 4 A activated molecular sieves (1.6 mm 
pellets) for water removal. At the end of this period ethanol 
was removed in vacuo and the residue was neutralized to pH 
7 with NaHCO powder before adding water (250 mL). The 
Solution was transferred in a separatory funnel and the 
product was extracted with ether (3x100 mL). The combined 
ether extracts were washed with water (75 mL), pre-dried 
with brine (75 mL), then dried over MgSO and filtered. 
After ether removal, the crude pale yellow liquid was 
subjected to vacuum transfer (0.5 mmHg, 60-80° C.). 
Diethyl 2,2,3,3,4,4-hexafluoroglutarate was obtained as a 
clear, low viscosity liquid (11.34g, 81%). H NMR (360 
MHz CDC1) & 1.38 (6H, t, J=7.2 Hz), 4.41 (4H, q, J=7.2 
Hz). 
Ethyl 5-(2-furyl)-5-oxo-2,2,3,3,4,4-hexafluoropentanoate 
(1). The following steps were performed in the absence of 
light. A solution of furan (0.9 mL, 12.4 mmol), in THF (30 
mL) was cooled to -78° C. prior to the addition of n-BuLi 
(3 mL, 2.5 M in hexane, 7.5 mmol). The mixture was stirred 
at room temperature for 3 h. The resulting 2-lithiofuran 
solution was added to a -78 C. solution of diethyl 2.2.3, 
3,4,4-hexafluoropentanoate (4.1 g, 13.8 mmol) in THF (100 
mL) over a 15 min period and allowed to stir for 30 min. 
Warm up and Simultaneous in vacuo removal of Solvent 
followed at the end of the stirring period. The yellow-red 
crude mixture was immediately purified with column chro 
matography on Silica gel. The diester was recovered during 
elution with hexanes and a 9:1 hexanes: EtOAc mixture 
(1.64 g., 39% recovery). The UV active product 1 (1.53 g, 
64% cacld from nBuLi), as a yellow oil, eluted with a 8:2 
hexanes: EtOAc combination. H NMR (360 MHz, CDC1, 
H-'F HETCOR cross peak) & 1.37 (3H, t, J=7.2 Hz), 4.43 
(2H, q, J=7.2 Hz), 6.65 (1H, dd, J=3.7, 1.6 Hz), 7.50 (1H, 
m), 7.80 (1H, d, J=1.6 Hz). 'C NMR (125 MHz, CDC1) 
813.9, 65.2, 108.7 (tt, J =266.4, 31.4 Hz, CF.), 110.9 (tt, 
J-2266.4, 33.3 Hz, CF), 111.0 (tt, J =266.4, 31.4 Hz, 
CF), 113.92, 125.6, 148.5, 151.0, 159.2 (t, J =29.6 Hz), 
171.4 (t, J =27.8 Hz). 'F NMR (470 MHz, CDC1) & 
-123.40 (2F, s), -118.69 (2F, t, J=10.0 Hz), -116.98 (2F, t, 
J=10.0 Hz). Anal. Calcd. for CHFO: C, 41.53; H, 2.53. 
Found: C, 41.80; H, 2.66. 
(1) 
O O 
O CF ls \ / CE,1 NCF, OEt 
1-Hydroxy-5-(2-furyl)-2,2,3,3,4,4-hexafluorooxane (2). 
Sodium borohydride (0.35 g, 9.25 mmol) was added to a 
stirred solution of 1 (1.53 g, 4.81 mmol) in anhydrous 
methanol (100 mL) at 0° C. After a 3 h period at that 
temperature, the Solvent was removed using a rotoevapora 
tor and the residue acidified to pH 2 with 2N HC1. The 
aqueous mixture was then neutralized with Saturated 
NaHCO prior to an extraction with ether (3x50 mL). The 
combined organic layers were dried with MgSO and con 
centrated. Product 2 (1.28 g., 96%) was obtained as a viscous 
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dark-yellow oil which was a 1:1 mixture of trans:cis-1,5-(2) 
diastereomers. The oil crystallized after Standing undis 
turbed for a 2 h period. Recrystallization from an anhydrous, 
acid-free 3:1 hexane:CHCl solution afforded X-ray quality 
crystals mp=89-90° C. in quantitative yield. The X-ray 
Structure revealed that the cis-2 diastereomer had undergone 
ring opening and closing to the crystal-forming trans-2 unit. 
The X-ray crystal structure determination of 2 is shown in 
FIG. 1. The trans-2 racemate is clearly visible in the cen 
trosymmetric unit cell. Exclusion of water from the NMR 
Solvent prevents the ring opening in Solutions and allows to 
record spectra of the single anomer. "H NMR of trans-2 (500 
MHz, CDC1, H-'FHETCOR cross peak) & 3.60 (1H, s), 
5.45 (1H, s), 5.52 (1H, d, J-23 Hz), 6.47 (1H, dd, J=3.2, 2.0 
Hz) 6.67 (1H, d, J=3.2 Hz), 7.51 (1H, d, J=1.2 Hz). 'C 
NMR of trans-2 (125 MHz, de- Acetone) & 642.2 (ddd, 
J-25.9, 18.5, 3.7 Hz), 91.5 (dd, J =38.8, 24.1 Hz), 
109.0 (CF), 111.0, 110.8 (CF), 113.9 (CF), 112.6, 143.3, 
144.3. 'F of trans-2 (470 MHZ, di- Acetone, 'F-'F 
COSY cross peak) 8 –143.9 (i1, dddddd, J=272.2, 13.8, 9.6, 
6.0 Hz), -132.0 (1F, ddt, J=274.2, 10.1, 10.0 Hz), -130.4 
(1F, dtddd, J=264.2,9.4, 8.9, 4.71, 1.4 Hz), -128.22 (1F, ddt, 
J=264.2, 15.0, 10.0 Hz), -125.6 (1F, ddddd, J=272.2, 7.3 
Hz), -121.6 (1F, ddtd, J=274.2, 16.8, 7.0 Hz). Anal. Calcd 
for CHFOs: C, 39.15; H, 2.19. Found: C, 39.25; H, 2.34. 
(2) 
1-O-Benzyloxy-5-(2-furyl)-2,2,3,3,4,4-hexafluorooxane 
(3). Benzoyl chloride (1.16 mL, 10.0 mmol) and TEA (3.0 
mL, 20 mmol) were added dropwise Simultaneously to a 
solution of crystalline 2 (2.32 g, 8.41 mmol) in 50 mL of 
CHCl at room temperature. The mixture was stirred at that 
temperature for 15 min before quenching with exceSS 
diethylamine. After an additional 15 min period the solvent 
was removed and the residue was immediately poured onto 
a silica gel column and eluted with a 9:1 hexane:EtOAc 
mixture. This operation efficiently removed the impurities in 
the form of triethylammonium chloride and N,N-diethyl 
benzamide giving the clear heavy oil 3 (3.11 g, 97%) as a 
15:1 mixture of tris:cis 1,5-disubstituted oxane by NMR. 
The mixture was carried to the next step without further 
purification. H NMR of trans-3 (500 MHz, CDC1) & 5.20 
(1H, dd, J=20.9, 3.62 Hz), 6.37 (1H, dd, J=15.31, 3.62 Hz), 
6.45 (1H, dd, J=3.23, 1.62 Hz), 6.70 (1H, d, J=3.23 Hz), 7.50 (3H, m), 7.64 (1H, m), 8.13 (2H, dd, J=8.06, 1.21 Hz). 'C 
NMR of trans-3 (125 MHz, CDC1) & 70.53 (ddd, J = 
22.2, 18.5, 3.7 Hz), 88.7 (ddd, J =29.6, 18.5, 5.6 Hz), 
109.0 (ddtt, J =283.0, 253.4, 29.6, 22.2 Hz, CF.), 110.5 
(ddddd, J =268.2, 260.8, 27.8, 24.0, 3.7 Hz, CF.), 111.0, 
111.6 (ddddd, J =268.2, 260.8, 27.7, 24.0, 3.7 Hz, CF) 
112.7, 127.4, 128.7, 130.5, 134.6, 1424, 144.5, 163.5. 'F 
NMR of trans-3 (470 MHz, CDC1) 8 –145.9 (1F, ditt, 
J=274.7, 15.3, 4.4 Hz), -137.0 (1F, dtd, J=263.8, 17.4, 8.7 
Hz), -133.6 (1F, ddt, J=261.6, 15.3, 8.7 Hz), -130.3 (1F, dm, 
J=266.4 Hz),429.0 (1F, ddt, J=265.9, 13.1, 10.9 Hz), -126.9 
(1F, dim, J-272.7 Hz). Anal. Calcd. for CHFO: C, 
50.54; H, 2.65. Found: C, 50.76; H, 2.48. 
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(3) 
5-O-Benzyloxy-2,2,3,3,4,4-hexofluorooxanoic acid (4). 
Oxidative removal of furyl was effected using RuO (5 mol 
%) that was added to a biphasic solution of water (180 mL), 
acetonitrile (60 mL), and CC1 (120 mL) containing 3 (2.93 
g, 7.71 mmol) and NalO (24.7 g., 116 mmol). The grey 
mixture was stirred vigorously for 5 days while monitored 
by TLC. The volatile solvents were removed and the aque 
ous residue extracted with EtOAc (3x150 mL) and dried 
with MgSO, filtered through celite and activated carbon. 
Solvent removal in vacuo cleanly afforded 4 as a white solid (2.65 g, 96% wet yield). H NMR (500 MHz, de-Acetone) 
83.6 (broad S, OH), 5.48 (1H, dmult, J=21.4 Hz), 6.59 (1H, 
dd, J=14.9, 3.62 Hz), 7.62 (2H, m), 7.78 (1H, m), 8.12 (2H, 
m). Anal. Calcd. for CHFOs: C, 45.59; H, 2.25. Found: 
C, 43.00; H, 2.25. The elemental analysis data shows the 
presence of H2O even after extensive drying. A Small 
amount of the hygroscopic acid product was quantitatively 
converted into the methyl ester derivative methyl 5-O- 
benzyloxy-2,2,3,3,4,4-hexafluorooxanoate (4a) by standard 
titration with diazomethane in ether Solution, and then fully 
characterized. "H NMR of 4a (500 MHz, (CDC1) & 3.87 
(3H, s), 4.71 (1H, m), 6.25 (1H, dd, J=14.5, 3.63 Hz), 7.50 (2H, m), 7.66 (1H.m), 8.12 (2H, m). 'C NMR of 4a (125 
MHz, CDC1) & 53.6, 72.1 (t, J =25.9 Hz), 88.2 (ddd, 
J-22.2, 18.5, 3.7 Hz), 108.5 (ddtt, J =281.2, 253.4, 
29.6, 20.3 Hz, CF), 110.1 (tdd, J =266.4, 29.6, 22.2 Hz, 
CF), 111.2 (tdd, J =257.1, 25.9, 20.5 Hz, CF), 127.2, 
128.8, 130.6, 134.7, 1617, 163.4 °F NMR (470 MHz, 
CDC1) 8 –145.4 (1F, ddduart, J=273.6, 12.7 Hz), -136.8 
(1F, dddtd, J=261.0, 14.7, 7.5, 2.4 Hz), -133.6 (1F, dddt, 
J=263.0, 15.4, 9.3, 5.8 Hz), -128.1 (2F, m), -126.7 (1F, dim, 
J=273.6 Hz). HRMS (El) m/z calcd for CHFOs 
372.0432, found 372.0434. 
(4) 
1-O-Benzyloxy-5-(5'-hydroxymethyl)-2,2,3,3,4,4- 
hexafluorooxane (5). A solution of 4 (2.3 g., 6.42 mmol) in 
THF (20 mL) at 0° C. was treated with 1M BH-THF 
complex (39 mL). The mixture was stirred at 0° C. for 20 
min, then at room temperature for 24 hr in a closed System. 
At the end of that period 1 MDIBAL-H in THF (19 mL), was 
15 
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added to the reaction mixture at room temperature and 
stirred for 30 min. The reaction was quenched with HO (20 
mL) at 0°C., treated with 20 mL 2M HCl, then neutralized 
with NaHCO, before extraction with EtOAc (3x150 mL). 
The organic extracts were dried with MgSO, filtered and 
concentrated. The crude clear heavy oil was purified by flash 
chromatography on Silica with a 10:1 mixture of hexane 
:ethyl acetate. Pure 5 (1.814g, 82%) was obtained as a pale 
yellow solid. "H NMR (500 MHz, CDC1) & 2.05 (1H, dd, 
J=8.5, 5.2 Hz), 4.02 (2H, m), 4.19 (1H, ddddd, J=20.1, 3.6 
Hz), 6.20 (1H, dd, J=11.3, 3.6 Hz), 7.50 (2H, m), 7.66 (1H, 
m), 8.13 (2H, m). 'C NMR (125 MHz, CDC1) & 558.3, 
74.6 (dd, J =27.7, 24.0 Hz), 88.7 (ddd, J =29.6, 
18.5, 5.5 Hz), 108.5 (ddtt, J =283.0, 253.4, 29.6, 20.3 Hz, 
CF), 110.4 (dddd, J =270.1, 264.5, 27.7, 24.0 Hz, CF), 
112.2 (dddd, J =270.1, 264.5, 27.7, 24.0 Hz, CF), 127.3, 
128.8, 130.4, 134.7, 163.7. 'F (470 MHz, CDC1) 8-146.7 
(1F, ditt, J=273.3, 13.9, 9.7 Hz), -137.1 (1F, dddt, J=262.2, 
15.3, 8.3, 2.8Hz), -134.0 (1F, dim, J=262.2 Hz), -132.4 (1F, 
ddtd, J=267.7, 13.9, 6.9, 4.2 Hz), -131.5 (1F, dim, J=266.4 
Hz), -127.2 (1F, dim, J=269.1 Hz). Anal. Calcd. for 
CHFO: C, 45.36; H, 2.93. Found: C, 45.47; H, 2.91. 
(5) 
1-Hydroxy-5-(5'-hydroxymethyl)-2,2,3,3,4,4- 
hexafluorooxane (6). A solution of 5 (0.497 g, 1.44 mmol) 
and KCO (65 mg, 0.47 mmol) in trifluoroethanol (20 mL) 
was stirred at room temperature for 12 h. After solvent 
removal, Saturated NaHCO Solution was added to the 
residue. The aqueous layer was extracted with pentane 
(3x50 mL) then acidified to pH 2 with 2N HCl followed by 
extraction with AcOEt (3x60 mL). The AcOEt extract was 
dried with MgSO and concentrated to yield 6 (0.347g, 99% 
crude) as a colorless heavy oil which crystallized during in 
vacuo removal of Solvent. The product was recrystallized 
from a 2:1 hexanes: EtO solution. The normal protocol 
followed in the NMR sample preparation was not sufficient 
to prevent equilibration of the cis and trans diastereomers in 
Solution. Qualitatively, compound 6 was Soluble in acetone, 
EtOAc, ether, and water; insoluble in CHCl and other 
solvents of lower polarity. H NMR of cis 1.5-(6) (500 MHz, 
d-Acetone, 'H-'F HETCOR cross peaks) & 3.82 (1H, 
dddd, J=12.1 6.9, 5.7, <0.5 unres. Hz), 3.95 (1H, dddd, 
J=12.1, 6.5, 4.0, 1.2 Hz), 4.18 (1H, ddtt, J=23.5, 7.0, 5.3, 1.4 
Hz), 4.35 (1H, dd, J=6.7, 5.7 Hz, 5'-OH), 5.31 (1H, dddd, 
J=15.7, 8.5, 4.4, 0.8 Hz), 7.34 (1H, d, J=8.3 Hz, 1-OH). H 
decoupled 'C NMR of cis 1.5-(6) (125 MHz, CDC1) & 58.3 
(d, J-6.5 Hz), 74.2 (dd, J-26.8, 22.2 Hz), 92.2 (ddd, J =27.7, 19.4, 4.62 Hz). 'F decoupled 'C NMR 
of cis 1.5-(6) (125 MHz, CDC1) & 109.7(CF), 111.6 (CF), 
113.5(CF). 'F of cis 1.5-(6) (470 MHz.d-Acetone, 'F- 
'F COSY cross peak) 8 –145.5 (1F, ddddtd, J=270.7, 14.7, 
14.0, 9.3, 0.8 Hz), -139.4 (1F, ddddddd, J=261.1, 16.1, 14.8, 
7.6., 1.42 Hz), -132.8 (1F, ddtd, J=267.5, 15.5, 9.3, 1.3 Hz), 
-131.7 (1F, ddddddd, J=264.5, 15.4, 13.8, 8.1, 1.4, 0.5 Hz), 
-130.4 (1F, ddtdd, J=264.5, 12.3, 9.4, 1.4, 0.8 Hz), -125.3 
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(1F, dddd, J-270.7, 13.9, 7.9, 40 Hz). "H NMR of trans 
1.5-(6) (500 MHz, de-Acetone, 'H-'F HETCOR cross 
peak) & 3.80 (1H, dddd, J=12.1, 6.9, 5.7, <0.5 unres. Hz), 
3.96, (1H, dddd, J=12.1, 6.5, 4.0, 1.2 Hz), 4.24 (1H, t, J=6.3 
Hz, 5'-OH), 4.52(1H, d unres.m., J=24.8 Hz), 5.55 (1H, dt, 
J=7.3, 6.0 Hz), 7.36 (1H, dt, J=5.6, 21 Hz, 1-OH). H 
decoupled 'C NMR of trans 1.5-(6) (125 MHz, CDC1) & 
58.2 (d, J =4.6 Hz), 69.1 (dd, J =26.8, 21.3 Hz), 
91.6 (ddd, J =36.1, 23.1, 2.8 Hz). 'F decoupled 'C 
NMR of trans 1,5-(6) (125 MHz, CDC1) & 109.0(CF), 
111.2 (CF), 113.5(CF) 'F of trans 1.5-(6) (470 MHz, 
d-Acetone, 'F-'F COSY cross peak) 8 –143.9 (1F, 
dddddd, J=269.5, 12.8, 10.0.8.0, Hz), -131.2 (1F, dtddd, 
J=263.2, 16.3, 12.6, 7.8, 1.7 Hz), -130.7 (1F, ddtdt, J=268.5, 
11.6, 3.7, 1.8, 1.0, 0.5 Hz), -129.3 (1F, ddddd, J=263.2, 
13.2, 9.8, 8.0, 1.8, 0.8 Hz), -123.4 (1F, dddtdd, J=269.4, 
15.1, 13.2, 7.5, 2.6, 2.1 Hz), -120.7 (1F, ddddddd, J=268.5, 
16.4, 15.4, 8.2, 7.3, 1.7, 0.9 Hz). Anal. Calcd. for CHFOs: 
C, 30.01; H, 2.52. Found: C, 29.97; H, 2.44. 
(6) 
1-O-Benzyloxy-5-(5'-O-Benzyloxymethyl)-2,2,3,3,4,4- 
hexafluorooxane (7). Compound 7 (134 mg., 93%) was 
obtained as a pale yellow Solid following the Same method 
as for 3 using alcohol 5 (113 mg, 0.32 mmol) or diol 6. The 
usual workup protocol followed by column chromatography 
and preparative TLC with 7:1 hexane:EtOAc as the eluent 
gives the product which is used for chiral Separation. The 
X-ray crystal structure determination for 7 is shown in FIG. 
2. "H NMR (500 Mhz, CDC1 & 4.50 (1H, dim, J-21.8 Hz), 
4.61 (1H, dd, J= 12.1, 6.9 Hz), 4.78 (1H, dd, J=12.1, 40 Hz), 
6.25 (1H, dd, J=14.9, 3.6 Hz), 7.45 (2H, m), 7.50 (2H, m), 
7.59 (1H, m), 7.66 (1H, m), 8.03 (2H, m). 'C NMR (125 
MHz, CDC1) & 59.5, 71.9 (dd, J =27.8, 24.1 Hz), 88.5 
(ddd, J =29.6, 18.5, 5.6 Hz), 108.5 (CF), 110.4 (CF), 
112.2 (CF), 127.3, 128.4,128.5, 128.8, 129.9, 130.5, 133.5, 
1346, 1634, 1659. 'F (470 MHz, CDC1) 8 -127.2 (1F, d 
unres.m., J=277.2 Hz), -130.4 (1F, ddtd, J=256.6, 9.9, 3.3 
Hz), -132.3 (1F, ditt, J=267.3, 8.3 Hz), -133.8 (1F, ddt, 
J=262.3, 24.7, 8.3 Hz), -137.0 (1F, ddtd, J=262.3, 16.5, 
14.9, 6.6 Hz), -146.2 (1F, d unres.m, J-273.9 Hz). Anal. 
Calcd. for CHFOs: C, 53.58; H, 3.15. Found: C, 53.24; 
H, 3.19. 
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(7) 
By following the same procedures as above, but employ 
ing the corresponding 2,2,3,3-tetrafluorodiethylbutanedioate 
as the Starting material, the following compounds were 
made: 
(cis)-1-hydroxy-4- 
(2-furyl)-2,2,3,3-tetrafluorofuran 
F F 
(trans)-1-hydroxy-4- 
(2-furyl)-2,2,3,3-tetrafluorofuran 
HO 
B-2,3-dideoxy 
2,2,3,3-tetrafluororibofuranose 
HO 
OH 
F F 
C-2,3-dideoxy 
2,2,3,3-tetrafluororibofuranose 
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(cis)-1-(9-(6-methoxypurinyl)-4- 
(1-butyl)-2,2,3,3-tetrafluorofuran 
N 
N N 
N N N 2 
OMe 
(trans)-1-(9-(6-methoxypurinyl)-4- 
(1-butyl)-2,2,3,3-tetrafluorofuran 
(cis)-1-(9-(6-aminopurinyl)-4- 
(1-butyl)-2,2,3,3-tetrafluorofuran 
N 
N n 
N N N 2 
(trans)-1-(9-(6-aminopurinyl)-4- 
(1-butyl)-2,2,3,3-tetrafluorofuran 
In an alternative embodiment according to the present 
invention, Starting materials for the process of the present 
invention of the following formula may be used: 
and a new reagent, benzyloxymethylzinc bromide, is used 
for introducing the 5'-hydroxymethyl moiety. This key 
reagent enables these inexpensive materials to be homolo 
gated to the proper number of carbon atoms in the ribose 
unit. 
1O 
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Compounds of the present invention are prepared accord 
ing to the following Scheme. 
O O 
i), ii), iii) 
He 
F F 
BzOCH2 O 
O 
F F iv), v), vi) 
F F 
BzOCH2 O Base 
F F 
F F 
i) Benzyl-O-CHZnBr, THF, -78 °C 
ii) NaBH4, 50% aq. MeOH, NaHCOs 
DCC or POCl3 
DIBAL-H 
v) MsC1, EtsN, CHCl2 
Silyated Base, Nal/CH3CN 
The hexose Sugar analogs according to the present inven 
tion are Similarly prepared from the corresponding perfluo 
roglutaric anhydride. 
The heavily fluorinated nucleoside analogs of the present 
invention may be used for the treatment of viral infections 
in the manner usual in the treatment of Such pathologies. The 
compounds may be effective for the treatment of viral 
infections in general, and particularly in the treatment of 
infections caused by retroviruses, such as HIV. 
The compounds may be effectively administered orally, 
topically or parenterally. In general, dosages in the range of 
from about 0.05 mg/kg to about 5000 mg/kg are useful, 
preferably in the range of from about 5 mg/kg to about 500 
mg/kg. 
The compounds may be used in medicine in the form of 
conventional pharmaceutical compositions. The formulation 
of the compositions is conventional, and follows the usual 
practices of pharmaceutical chemists. When a heavily flu 
orinated nucleoside analog of the present invention is to be 
administered topically, it is formulated as a topical 
composition, Such as a cream or ointment to be rubbed into 
the affected tissue. Creams are emulsions of an oily phase 
and an aqueous phase, in which the heavily fluorinated 
nucleoside analogs are dissolved or Suspended. Ointments 
are greasy or waxy compositions, in which the nucleoside 
may be soluble but may be suspended, if it is insoluble at the 
desired concentration. Topical formulations preferably fur 
ther include a transdermal agent, Such as DMSO, propylene 
glycol, or the like. 
Parenteral compositions may be preferably formulated in 
Such a way that the heavily fluorinated nucleoside can be 
dissolved for injection. Alternatively, the heavily fluorinated 
nucleoside may be formulated as a dried powder with 
physiologically-acceptable Suspending agents, Such as 
Starch, Sugar and the like, to which Sterilized water is added 
to form a Suspension to be injected. Parenteral compositions 
can be formulated in aqueous bases containing moderate 
amounts of physiologically-acceptable Solvents, Such as 
propylene glycol and the like, and Such compositions may be 
capable of dissolving the present heavily fluorinated nucleo 
Side analogs at acceptable concentrations. 
A great many types of orally administered compositions 
are in common use, including unit dosage forms Such as 
tablets and capsules, and liquid dosage forms Such as 
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Suspensions. In general, unit dosage forms are preferred in 
pharmacy and are formulated in Such a way as to provide the 
usual dose in one or a Small number of tablets or capsules. 
The formulation of tablets, making use of appropriate 
lubricants, binding agents and disintegration agents, is and 
long has been thoroughly understood by pharmaceutical 
chemists. The formulation of capsules involves only the 
dilution of the heavily fluorinated nucleoside analogs with 
an appropriate proportion of an inert powdery Substance, 
Such as lactose, to provide the proper bulk to fill the desired 
Size of capsule. 
The description above should not be construed as limiting 
the Scope of the invention, but as merely providing illustra 
tions to some of the presently preferred embodiments of this 
invention. In light of the above description and examples, 
various other modifications and variations will now become 
apparent to those skilled in the art without departing from 
the Spirit and Scope of the present invention as defined by the 
appended claims. Accordingly, the Scope of the invention 
should be determined Solely by the appended claims and 
their legal equivalents. 
What is claimed is: 
R1 
F R 2 
O 
F F 
F 
F F 
wherein R is Selected from alkyl, alkenyl, aryl, -CH2 
O-alkyl, -CH-O-aryl, -CHOPOH, -CH-O- 
carbohydrate, 
wherein R is selected from hydroxy, -O-carbohydrate, 
NH2 
es N 
O 
O 
HN 
1. 
R4 s 
N21 N 
N Or 
wherein R is Selected from H, halogen, lower alkyl, 
lower alkenyl, lower haloalkyl, lower haloalkenyl, 
amino, mono- or di-lower alkylamino; 
wherein R is Selected from amino, hydroxy, alkoxy, or 
halogen; and 
wherein Rs is H or amino, including all Stereoisomers 
thereof. 
HN 
1s, Rs 
N 
N 
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2. The compound according to claim 1 wherein R is 
3. The compound claim 2 wherein is 
lower alkyl. 
according to 
4. The compound claim 3 wherein is 
methyl. 
according to 
5. The compound claim 3 wherein is 
ethyl. 
6. The compound 
lower halo alkyl. 
according to 
according to claim 2 wherein is 
7. The compound claim 6 wherein is 
trifluoromethyl. 
according to 
8. The compound claim 2 wherein is 
bromoethenyl. 
according to 
9. The compound according to claim 2 wherein is 
monoloweralkylamino. 
10. The compound according to claim 9 wherein R is 
methylamino. 
11. The compound according to claim 2 wherein R 
halogen. 
12. The compound according to claim 11 wherein R is 
iodo. 
13. The compound according to claim 11 wherein R is 
fluoro. 
14. The compound according to claim 1 wherein R is 
NH2. 
N4 
1st O 
R4 
Na N 
16. The compound according to claim 15 wherein R is 
hydroxy. 
17. The compound according to claim 15 wherein R is 
amino. 
6,013,790 
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18. The compound according to claim 1 wherein R is 
O 
N 
HN N 5 
ls N 
Rs N 
1O 
19. The compound according to claim 18 wherein Rs is 
amino. 
20. The compound according to claim 18 wherein Rs is H. 
21. The compound according to formula (II): 
15 
II 
R1 
F 
o, is 
F F 
2O 
F 
F F 
wherein R is selected from alkyl, alkenyl, aryl, 
-CH-OH, -CH2-O-alkyl, -CH2-O-ary 1, 25 
–CHOPOH: 
wherein R is Selected from hydroxy, 
O NH2 
3O 
R 
HN 3 N21 
1. es. 
35 
R4 O 
N N 
N21 N HN N ls ls 40 N N N N 
N Rs N 
Or 
wherein Rs is selected from H, halogen, lower alkyl, as lower alkenyl, lower haloalkyl, lower haloalkenyl, 
amino, mono- or di-lower alkylamino; 
wherein R is Selected from amino, hydroxy, alkoxy, or 
halogen; and 
wherein Rs is H or amino; including all stereoisomers so 
thereof. 
22. A process for preparation of a heavily fluorinated 
Sugar derivative comprising the Steps of: 
(a) converting one of the carboxylic ester groups of 
Formula (IV): 55 
loweralkyl-O-C(O)-(CF)-C(O)-O-loweralkyl (IV) 
wherein n=2 or 3, to the ketone to yield compounds of 
Formula (V): 
60 
2-furyl-C(O)-(CF)-C(O)-O-loweralkyl (V) 
(b) contacting a compound of Formula (V) with a reduc 
ing agent to form compounds of Formula (VI): 
22 
(VI) 
\ N 
O 
(CF2) 
C-OH 
H 
(c) protecting the hydroxy group of the compound of 
Formula (VI) to form compounds of Formula (VII): 
(VII) 
N 
O 
(CF2) 
-O-Protecting Group 
(d) oxidatively removing the furyl group from the com 
pound of Formula (VII) to produce compounds of 
Formula (VIII): 
st (CR) - 
(VIII) 
-O-Protecting Group 
(e) reducing the carboxyl group of the compound of 
Formula (VIII) to a hydroxymethyl to form compounds 
of Formula (IX): 
r 
(DX) 
OH 
(CF2) 
5-O-Protecting Group. 
23. The process according to claim 22, further comprising 
the Step of removing the protecting group of the compound 
of Formula (IX) to produce compounds of Formula (X): 
6,013,790 
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(X) 
OH (XI) 
O-Protecting Group 
5 r (CE) --O 
(CR) - 
C-OH. 1O 
-O-Protecting Group. 
24. The process according to claim 22, further comprising 
the Step of protecting the hydroxy group of formula (IX) to 
form compounds of Formula (XI): k . . . . 
